Amicus Therapeutics ApS: Financial statements 2022
CVR: 39359340
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 1,575,511 and a net result of DKK 54,033 compared with DKK 19,351 the year before. That is an increase of 144.6% compared with the year before. Equity in the 2022 report amounted to DKK 303,093. The solvency ratio was 49.1%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,575,511
- Profit/Loss
- DKK 54,033
- Equity
- DKK 303,093
- Total Assets
- DKK 617,319
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 1.6 mio. | 54 t. | 303 t. | 1 |
| 2021 | - | 644 t. | 19 t. | 249 t. | 1 |
| 2020 | - | 490 t. | 22 t. | 230 t. | 1 |
| 2019 | - | 2 mio. | 84 t. | 208 t. | 2 |
| 2018 | - | 2 mio. | 74 t. | 124 t. | 2 |
Official annual report
Keep an eye on Amicus Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Amicus Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK 644,168, and the net result was DKK 19,351.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The board consists of Richard Gideon Morris (chair), Brian Keogh and Steven John Green. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity in the 2025 report amounted to DKK 424,641.